Outlining treatment methods and limitations for oropharyngeal cancer

Abstract

Oropharyngeal cancers are a prevalent form of the disease that affects approximately 1 in 60 men and 1 in 140 women. The tonsils are the most common site of oropharyngeal cancer, accounting for 23.1% of all cancers in this region [1]. In over 50% of oropharyngeal squamous cell carcinomas (OPSCC), the p53 gene is mutated [2,3]. This mutation on chromosome 17q13 can lead to a lack of growth control which prevents cells from responding to stress or DNA damage [2,3]. This viewpoint explores risk factors that are increasing the prevalence of OPSCC. Novel approaches for clinical treatment of oropharyngeal cancers are reviewed and compared to current treatments. Limitations for all treatment methods are discussed, demonstrating the need for continued research in the field.